{"id":"camrelizumab-apatinib-tmz","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Camrelizumab binds to PD-1, preventing its interaction with PD-L1 and thus activating T cells to attack cancer cells. Apatinib inhibits VEGFR, which is involved in angiogenesis, a process that tumors use to grow their own blood supply. TMZ works by causing DNA crosslinks, which prevent cancer cells from replicating.","oneSentence":"Camrelizumab is a PD-1 inhibitor, apatinib is a VEGFR inhibitor, and TMZ is a chemotherapy agent that works by crosslinking DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:47.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Glioblastoma"}]},"trialDetails":[{"nctId":"NCT05789043","phase":"PHASE3","title":"Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-03-21","conditions":"Acral Melanoma","enrollment":140},{"nctId":"NCT04397770","phase":"PHASE2","title":"Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2020-05","conditions":"Melanoma","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"camrelizumab+apatinib+TMZ","genericName":"camrelizumab+apatinib+TMZ","companyName":"Peking University Cancer Hospital & Institute","companyId":"peking-university-cancer-hospital-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camrelizumab is a PD-1 inhibitor, apatinib is a VEGFR inhibitor, and TMZ is a chemotherapy agent that works by crosslinking DNA. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Glioblastoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}